Tag: orphan disease

May 17, 2018

Resverlogix CEO Discusses Phase 3 BETonMACE Clinical Trial

Aside from the recent funding and Phase 3 trial news, Resverlogix has many milestones for investors to look forward to...
May 10, 2018

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of...
April 12, 2018

Innovation and Opportunities in the CBD Therapeutics Market

Kalytera Therapeutics CEO Bob Farrell shares his insight into the growing market for cannabinoid-based pharma products in this interview.
April 13, 2017

An Introduction to TSXV Life Science Stocks

Should you decide that the TSXV is right for you, the Investing News Network has compiled a list of some...
March 9, 2017

Genetics Facts for Investors

Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand....
February 16, 2017

TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer,...
February 16, 2017

Kalytera Therapeutics Completes Acquisition of Talent Biotechs

Kalytera Therapeutics, Inc. (TSX-V:KALY) (“Kalytera”) announced today that it has successfully completed the previously announced acquisition (the “Acquisition”) of Talent...